Target intelligence / Profile preview

Cyclic nucleotide-gated channel subunit alpha-4 (CNGA4)

Target
CNGA4
Molecular classification
Ion channel, Cyclic nucleotide-gated channel, Membrane protein
01

Overview

Cyclic nucleotide-gated channel subunit alpha-4 (CNGA4) is a modulatory subunit of olfactory cyclic nucleotide-gated (CNG) ion channels, primarily expressed in sensory neurons of the olfactory epithelium[1][3][5]. It combines with other subunits (mainly CNGA2 and CNGB1b) to form heterotetrameric channels responsible for converting odorant signals into electrical impulses by allowing calcium and sodium ions to enter the neuron when activated by cyclic nucleotides like cAMP or cGMP[2][4][6]. CNGA4's presence is crucial for rapid adaptation to odorants, achieved via Ca²⁺-calmodulin-dependent feedback inhibition, allowing olfactory neurons to quickly adjust their sensitivity to persistent stimuli[2][3]. Mutations in CNGA4 have been linked to specific retinal and multisystemic diseases, but as of now, the protein is not a target for approved drug therapies. CNGA4 serves mainly as a molecular component in the physiology of smell rather than a direct pharmacological target[1][2][5].

Other names
CNG channel alpha-4CNGa4OCNC2OCNCbCNG5Olfactory cyclic nucleotide-gated channel subunit 2CNCA2CNG-4CNG4CNGB2 (historical/misused, see notes)OCNCBETAcyclic nucleotide-gated channel alpha-4cyclic nucleotide gated channel alpha 4cyclic nucleotide-gated cation channel alpha-4
02

Mechanism of action

Blockade: Non-specific blockade by cyclic nucleotide-gated channel inhibitors. Modulation: Activity modulated by cyclic nucleotides (cAMP, cGMP), calcium/calmodulin for channel adaptation. No approved direct therapeutic mechanism via CNGA4.

03

Biological functions

Signal transduction (olfactory/odorant signaling)Cation (Na⁺, Ca²⁺) transportSensory perception of smellRapid adaptation to odor stimuli
04

Disease associations

Retinitis pigmentosa (specifically type 45)Bardet-Biedl syndrome 13Other (limited known direct disease associations; mutation studies)
05

Safety considerations

Not a direct therapeutic target, so no known drug-related safety concernsPotential concerns: Loss-of-function mutations can impair olfactory adaptation but do not disrupt olfactory neuron development
06

Interacting drugs

None specifically reported for direct therapeutic/toxicological effect

2 more in the full profile.

07

Biomarkers

None in clinical useExperimental marker for olfactory sensory neuron function or adaptation

Beyond the preview

Go deeper on Cyclic nucleotide-gated channel subunit alpha-4 (CNGA4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclic nucleotide-gated channel subunit alpha-4 (CNGA4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call